Hangzhou 1gene Technology Co., Ltd. announced a private placement of common shares for gross proceeds of CNY 30 million on November 7, 2022. The transaction will include participation from new investor, ChengDa Pharmaceuticals Co., Ltd. which will acquire 12% equity stake in the company. After this capital increase, the registered capital of company will be increased from CNY 20,393,939 to CNY 23,174,931.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.63 CNY | -0.72% | -7.36% | -18.88% |
1st Jan change | Capi. | |
---|---|---|
-18.88% | 434M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 301201 Stock
- News ChengDa Pharmaceuticals Co., Ltd.
- Hangzhou 1gene Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from ChengDa Pharmaceuticals Co., Ltd.